Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies

BACKGROUND: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is considered the cornerstone in treatment of hematological malignancies. However, relapse of the hematological disease after allo-HSCT remains a challenge and is associated with poor long-term survival. Chimeric antigen rece...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jun, Zhong, Jiang F., Zhang, Xi, Zhang, Cheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5282795/
https://www.ncbi.nlm.nih.gov/pubmed/28143567
http://dx.doi.org/10.1186/s13045-017-0405-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5282795/
https://www.ncbi.nlm.nih.gov/pubmed/28143567
http://dx.doi.org/10.1186/s13045-017-0405-3

Ejemplares similares